COPD: Rauchen ist nicht der einzige Risikofaktor

Barczok, Michael

doi:10.1007/s15006-019-0718-y

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although smoking has long been considered to be the most important risk factor for COPD, approximately 25-45% of COPD patients have no smoking history, which indicates that other factors may play important roles in the occurrence and development of COPD ( Mannino and Buist, 2007 ; Salvi and Barnes, 2009 ; Barczok, 2019 ). Recent clinical studies have shown that low BMI is an important independent risk factor for poor prognosis in COPD patients ( Schols et al., 1998 ).…”

Section: Introductionmentioning

confidence: 99%

Analysis of the correlation between BMI and respiratory tract microbiota in acute exacerbation of COPD

Cao

Chen

Shu

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

ObjectiveTo investigate the distribution differences in the respiratory tract microbiota of AECOPD patients in different BMI groups and explore its guiding value for treatment.MethodsSputum samples of thirty-eight AECOPD patients were collected. The patients were divided into low, normal and high BMI group. The sputum microbiota was sequenced by 16S rRNA detection technology, and the distribution of sputum microbiota was compared. Rarefaction curve, α-diversity, principal coordinate analysis (PCoA) and measurement of sputum microbiota abundance in each group were performed and analyzed by bioinformatics methods.Results1. The rarefaction curve in each BMI group reached a plateau. No significant differences were observed in the OTU total number or α-diversity index of microbiota in each group. PCoA showed significant differences in the distance matrix of sputum microbiota between the three groups, which was calculated by the Binary Jaccard and the Bray Curtis algorithm. 2. At the phylum level, most of the microbiota were Proteobacteria, Bacteroidetes Firmicutes, Actinobacteria, and Fusobacteria. At the genus level, most were Streptococcus, Prevotella, Haemophilus, Neisseria and Bacteroides. 3. At the phylum level, the abundance of Proteobacteria in the low group was significantly higher than that in normal and high BMI groups, the abundances of Firmicutes in the low and normal groups were significantly lower than that in high BMI groups. At the genus level, the abundance of Haemophilus in the low group was significantly higher than that in high BMI group, and the abundances of Streptococcus in the low and normal BMI groups were significantly lower than that in the high BMI group.Conclusions1. The sputum microbiota of AECOPD patients in different BMI groups covered almost all microbiota, and BMI had no significant association with total number of respiratory tract microbiota or α-diversity in AECOPD patients. However, there was a significant difference in the PCoA between different BMI groups. 2. The microbiota structure of AECOPD patients differed in different BMI groups. Gram-negative bacteria (G-) in the respiratory tract of patients predominated in the low BMI group, while gram-positive bacteria (G+) predominated in the high BMI group.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of the correlation between BMI and respiratory tract microbiota in acute exacerbation of COPD

Cao

Chen

Shu

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

Vitamin D and its therapeutic relevance in pulmonary diseases

Ahmad

Arora

Khan

et al. 2021

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

Trends in burden of chronic obstructive pulmonary disease in Iran, 1995–2015: findings from the global burden of disease study

et al. 2020

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder that progresses over time, and currently it is the fourth leading cause of death across the globe. The World Health Organization (WHO) predicts that the disease will become the third leading cause of death by 2030. The present study aimed to assess the burden trends of COPD in Iran by estimating the disability-adjusted life years (DALYs) from 1995 to 2015. Methods Data were retrospectively collected as the Global Burden of Disease (GBD) from 1995 to 2015 and published by the Institute for Health Metrics and Evaluation. We applied DALYs, incidence and prevalence rate to report the burden of COPD in Iran. To assess the statistical significance according to trend, the Cochran-Armitage test was applied. Additionally, the t-test was used to analyze the DALYs number by gender and Onaway ANOVA by age groups at a significance level set atP < 0.05. Results From 1995 to 2015, there were approximately 1.1 million DALYs attributable to COPD in Iran. In both genders and at all ages, the number of DALYs increased significantly from 176,224 in 1995 to 253,618 in 2015. The incidence and prevalence rate were 76.65 and 1491.37 per 100,000 population, respectively in both genders in 2015 in Iran. It is noticeable that the number of deaths during the study years, 1995 to 2015, was 39,064. This study showed that the COPD burden was significantly different by age groups and gender. Conclusions COPD is still a public health problem in Iran and has an increasing trend. The majority of DALYs were due to the years of life lost as a result of premature death (YLLs), indicating that prevention and early detection, especially in the age groups of 15 to 70 years, should be considered.

show abstract

COPD: Rauchen ist nicht der einzige Risikofaktor

Cited by 4 publications

References 1 publication

Analysis of the correlation between BMI and respiratory tract microbiota in acute exacerbation of COPD

Analysis of the correlation between BMI and respiratory tract microbiota in acute exacerbation of COPD

Vitamin D and its therapeutic relevance in pulmonary diseases

Trends in burden of chronic obstructive pulmonary disease in Iran, 1995–2015: findings from the global burden of disease study

Contact Info

Product

Resources

About